AdvaCare is a CE, ISO and USFDA manufacturer of Hepatitis Test Kits.
Hepatitis test kits detect antibodies in the serum/plasma or blood through the use of specific complementary antibody markers. Diagnosis consists of one screening test.
The hepatitis A IgM virus test detects the IgM antibodies produced by the body in defense against the virus.
The HBsAb hepatitis B surface antibody test detects the antibodies complementary to the hepatitis B antigens presented on cells during infection by the hepatitis B virus.
The hepatitis C virus test detects cells of the immune system raised specifically against the hepatitis C virus.
The hepatitis E IgM virus test detects the IgM antibodies produced by the immune system in defense against the hepatitis E virus.
The test time varies depending on which test is taken. In the case of a hepatitis-positive result, one should consult with their doctor to consider the first stage of treatment. Our hepatitis test kits are 98-99% accurate and reliable.
There are certain external factors which may hinder or interfere the result of the test (in case some herbs or other natural products); due to this reason the test has to be re-administered.
Hepatitis refers to an inflammatory condition of the liver. It’s commonly caused by a viral infection, but there are other possible causes of hepatitis. These include autoimmune hepatitis and hepatitis that occurs as a secondary result of medications, drugs, toxins, and alcohol. Autoimmune hepatitis is a disease that occurs when your body makes antibodies against your liver tissue. The condition can be self-limiting or can progress to fibrosis and cirrhosis. There are 5 types of viral hepatitis – A, B, C, D, and E. Each type of hepatitis is caused by an unrelated virus that exerts a specific effect on the liver.
HEPATITIS A is caused by an infection with the hepatitis A virus (HAV). This type of hepatitis is most commonly transmitted by consuming food or water contaminated by feces from a person infected with hepatitis A. The average incubation period is 28 days before the acute symptoms begin to develop, including jaundice, abdominal pain, loss of appetite, nausea, fever, diarrhea, and fatigue.
There is a vaccination (HAV) which is administered in two divided doses. A combination vaccine is available for hepatitis A and B, called Twinrix. In addition to an immune globulin, medication can be prescribed within two weeks of contact with an infected individual.
HEPATITIS B is an acute and chronic illness that can be transmitted through blood and infected bodily fluids. Acute hepatitis B causes symptoms to appear quickly in adults. Infants infected at birth rarely develop only acute hepatitis B. Nearly all hepatitis B infections in infants go on to become chronic.
Chronic hepatitis B develops slowly. Symptoms may not be noticeable unless complications develop. On average the incubation period is 75 days before the acute symptoms begin to develop, including jaundice, abdominal pain, loss of appetite, nausea, fever, diarrhea, and fatigue.
Chronic symptoms include cirrhosis of the liver and liver cancer. Children below the age of six are those highest at risk. There is a vaccination (HBV) which is administered in a series of three to four shots. A combination vaccine called Twinrix is available for hepatitis A and B.
HEPATITIS C comes from the hepatitis C virus (HCV). Hepatitis C is transmitted through direct contact with infected body fluids, typically through injection drug use and sexual contact. On average the incubation period is 40 days before the symptoms begin to develop, including jaundice, abdominal pain, loss of appetite, nausea, joint pain, and fatigue. Hepatitis C can be prevented through the practice of good hygiene and the use of a condom during sexual intercourse. There is currently no vaccine against hepatitis C.
HEPATITIS D is an acute and chronic illness that can be transmitted through blood and infected body fluids. Hepatitis D is caused by a sub-viral satellite that requires the helper function of the hepatitis B virus to infect an individual.
The presence of both hepatitis D and B viruses can result in either a co-infection or a super-infection by the HDV. Hepatitis D causes an increased likelihood of liver failure and a rapid progression to liver cirrhosis. HDV also has the highest mortality rate of all the hepatitis diseases, at 20%, with higher risks of transmission by injecting drug users and a patient taking clotting factor concentrate. Individuals suffering from chronic hepatitis B carry a high risk of contracting HDV.
HEPATITIS E is an acute illness that can be transmitted through blood and infected bodily fluids. On average the incubation period is 40 days before the acute symptoms begin to develop, including fatigue, loss of appetite, weight loss, abdominal pain, jaundice, muscle soreness and fever. Hepatitis E can be prevented through the practice of good hygiene and the use of a condom during sexual intercourse. A vaccination was produced in 2011 (HEV) however it is not yet globally available.
Hepatitis is highly prevalent in Africa, eastern European countries and Asian countries. The incidence and mortality rates vary with region and virus type.
Hepatitis A is the most common with over 300 million infected worldwide. In contrast, hepatitis C has a much lower infection rate but contributes to the most fatalities.
Hepatitis D is prevalent in the Mediterranean region, sub-Saharan Africa, Middle East and northern regions of South America.